You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 48 No. 4, April 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Clonidine Treatment of Gilles de la Tourette's Syndrome

James F. Leckman, MD; Maureen T. Hardin, MSN; Mark A. Riddle, MD; John Stevenson, MA; Sharon I. Ort, RN, MPH; Donald J. Cohen, MD

Arch Gen Psychiatry. 1991;48(4):324-328.


Abstract

• The safety and effectiveness of clonidine hydrochloride (3 to 5 µg/kg per day) were evaluated in 47 subjects with Gilles de la Tourette's syndrome, aged 7 to 48 years. Twenty-four subjects were randomly assigned to clonidine treatment and 23 to placebo. Forty subjects (21 given clonidine and 19 placebo) successfully completed the 12-week, double-blind clinical trial. Clinical ratings of tic severity improved for both groups. The magnitude of response was greater in the group receiving clonidine. Clinician-rated measures of motor tic severity, the degree to which the tics are "noticeable to others," motor tic counts from videotaped interviews, and parent-rated measures of impulsivity and hyperactivity were the most responsive to clonidine treatment. These results indicate that clonidine is more effective than placebo in reducing some of the tic and other behavioral symptoms associated with Gilles de la Tourette's syndrome.



Author Affiliations

From the Child Study Center (Drs Leckman, Riddle, Cohen, Mss Hardin and Ort, and Mr Stevenson), the Children's Clinical Research Center (Dr Leckman), and the Departments of Psychiatry (Drs Leckman and Cohen) and Pediatrics (Drs Leckman and Cohen), Yale University School of Medicine, New Haven, Conn.


Footnotes

Accepted for publication October 24, 1990.

Reprint requests to Child Study Center, Yale University School of Medicine, PO Box 3333, New Haven, CT 06510 (Dr Leckman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing
Vetter et al.
Circulation 2008;117:2407-2423.
FULL TEXT  

Atomoxetine Treatment of ADHD in Children With Comorbid Tourette Syndrome
Spencer et al.
J Atten Disord 2008;11:470-481.
ABSTRACT  

Literature Review: Beyond Methylphenidate: Nonstimulant Medications for Youth With ADHD
Wood et al.
J Atten Disord 2007;11:341-350.
ABSTRACT  

Gilles de la Tourette's syndrome and its impact in the UK
Stern et al.
Postgrad. Med. J. 2005;81:12-19.
ABSTRACT | FULL TEXT  

Separation Anxiety Triggered by Atypical Neuroleptic Medication in an Adolescent with Tourette's Syndrome
Becker et al.
Clin Child Psychol Psychiatry 2004;9:597-603.
ABSTRACT  

A placebo-controlled trial of risperidone in Tourette syndrome
Scahill et al.
Neurology 2003;60:1130-1135.
ABSTRACT | FULL TEXT  

Psychopharmacology and Aggression: II. A Meta-Analysis of Nonstimulant Medication Effects on Overt Aggression-Related Behaviors in Youth with SED
Connor et al.
Journal of Emotional and Behavioral Disorders 2003;11:157-168.
ABSTRACT  

A placebo-controlled study of lofexidine in the treatment of children with tic disorders and attention deficit hyperactivity disorder
Niederhofer et al.
J Psychopharmacol 2003;17:113-119.
ABSTRACT  

A Double-blind Comparison of Desipramine and Placebo in Children and Adolescents With Chronic Tic Disorder and Comorbid Attention-Deficit/Hyperactivity Disorder
Spencer et al.
Arch Gen Psychiatry 2002;59:649-656.
ABSTRACT | FULL TEXT  

Height Distribution in Children With Tourette Syndrome
Zelnik et al.
J Child Neurol 2002;17:200-204.
ABSTRACT  

Treatment of ADHD in children with tics: A randomized controlled trial
Neurology 2002;58:527-536.
ABSTRACT | FULL TEXT  

A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder
Scahill et al.
Am. J. Psychiatry 2001;158:1067-1074.
ABSTRACT | FULL TEXT  

Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial
Singer et al.
Neurology 2001;56:599-604.
ABSTRACT | FULL TEXT  

Tourette syndrome, associated conditions and the complexities of treatment
Robertson
Brain 2000;123:425-462.
ABSTRACT | FULL TEXT  

Predictors of Clonidine Response in Tourette Syndrome: Implications and Inferences
Lichter and Jackson
J Child Neurol 1996;11:93-97.
ABSTRACT  

Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update
Baker et al.
J Psychopharmacol 1995;9:273-280.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.